npj Vaccines, Journal Year: 2024, Volume and Issue: 9(1)
Published: Sept. 7, 2024
Language: Английский
EBioMedicine, Journal Year: 2024, Volume and Issue: 100, P. 104963 - 104963
Published: Jan. 5, 2024
Glioblastoma (GBM) is one of the most lethal central nervous systems (CNS) tumours in adults. As supplements to standard care (SOC), various immunotherapies improve therapeutic effect other cancers. Among them, tumour vaccines can serve as complementary monotherapy or boost clinical efficacy with immunotherapies, such immune checkpoint blockade (ICB) and chimeric antigen receptor T cells (CAR-T) therapy. Previous studies GBM have suggested that few neoantigens could be targeted due low mutation burden, single-peptide vaccination had limited control monotherapy. Combining diverse antigens, including neoantigens, tumour-associated antigens (TAAs), pathogen-derived optimizing vaccine design strategy may help improvement. In this review, we discussed current platforms, evaluated potential antigenic targets, challenges, perspective opportunities for
Language: Английский
Citations
33
Cellular and Molecular Immunology, Journal Year: 2024, Volume and Issue: 21(12), P. 1354 - 1375
Published: Oct. 15, 2024
Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human adults. The standard care offers minimal clinical benefit, most GBM patients experience recurrence after treatment. In recent years, significant advancements have been made the development novel immunotherapies or other therapeutic strategies that can overcome immunotherapy resistance many advanced cancers. However, benefit immune-based treatments limited because unique immune profiles, cell heterogeneity, immunosuppressive microenvironment. this review, we present a detailed overview current immunotherapeutic discuss challenges potential molecular mechanisms underlying GBM. Furthermore, provide in-depth discussion regarding GBM, which will likely require combination therapies.
Language: Английский
Citations
28
Vaccines, Journal Year: 2024, Volume and Issue: 12(2), P. 191 - 191
Published: Feb. 13, 2024
Vaccines are essential tools to prevent infection and control transmission of infectious diseases that threaten public health. Most agents enter their hosts across mucosal surfaces, which make up key first lines host defense against pathogens. Mucosal immune responses play critical roles in provide durable better recall responses. Substantial attention has been focused on developing effective vaccines elicit robust localized systemic by administration via routes. yield protection superior parenterally delivered vaccines. Beyond valuable immunogenicity, can be less expensive easier administer without a need for injection materials more highly trained personnel. However, faces many challenges, much effort directed at development. In this article, we review the history vaccine development present an overview compartment biology immunity plays defending infection, knowledge helped inform We explore new progress design optimization novel approaches created improve efficacy safety
Language: Английский
Citations
25
MedComm, Journal Year: 2025, Volume and Issue: 6(2)
Published: Jan. 16, 2025
Rapid advances in vaccine technology are becoming increasingly important tackling global health crises caused by respiratory virus infections. While traditional vaccines, primarily administered intramuscular injection, have proven effective, they often fail to provide the broad upper tract mucosal immunity, which is urgently needed for first-line control of viral Furthermore, vaccines may not adequately address immune escape emerging variants. In contrast, developed using body's response mechanism can simultaneously establish both systemic and immunity. This dual action effectively allows system function as first line defense, preventing infections at entry points. review highlights efficacy including innovative delivery methods such nasal oral formulations, enhancing local barriers. Notably, offer potential advantages protecting against variants maintaining long-term multidimensional memory tract. addition, a combination largely improves their coverage effectiveness, providing valuable insights future development public inoculation strategies.
Language: Английский
Citations
3
Vaccines, Journal Year: 2023, Volume and Issue: 11(10), P. 1585 - 1585
Published: Oct. 12, 2023
Inducing humoral and cytotoxic mucosal immunity at the sites of pathogen entry has potential to prevent infection from getting established. This is different systemic vaccination, which protects against development symptoms. The field vaccination seen fewer technological advances compared nucleic acid subunit vaccine for injectable platforms. advent next-generation adenoviral vectors given a boost research. Basic research into mechanisms regulating innate adaptive discovery effective safe adjuvants will continue improve design. results clinical trials inhaled COVID-19 vaccines demonstrate their ability induce proliferation T cells production secreted IgA IgG antibodies locally, unlike intramuscular vaccinations. However, these immune responses par with review summarizes function respiratory mucosa-associated lymphoid tissue advantages that provide as
Language: Английский
Citations
33
Advanced Materials, Journal Year: 2023, Volume and Issue: unknown
Published: Dec. 4, 2023
Promising advances in molecular medicine have promoted the urgent requirement for reliable and sensitive diagnostic tools. Electronic biosensing devices based on field-effect transistors (FETs) exhibit a wide range of benefits, including rapid label-free detection, high sensitivity, easy operation, capability integration, possessing significant potential application disease screening health monitoring. In this perspective, tremendous efforts achievements development high-performance FET biosensors past decade are summarized, with emphasis interface engineering FET-based electrical platforms biomolecule identification. First, an overview strategies modulation recognition element design is discussed detail. For further step, applications vitro detection real-time monitoring biological systems comprehensively reviewed. Finally, key opportunities challenges electronic discussed. It anticipated that comprehensive understanding will inspire additional techniques developing highly sensitive, specific, stable as well emerging designs next-generation electronics.
Language: Английский
Citations
26
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: Sept. 11, 2024
Language: Английский
Citations
10
Advanced Materials, Journal Year: 2024, Volume and Issue: 36(15)
Published: Jan. 17, 2024
In the past decade, adoptive cell therapy with chimeric antigen receptor-T (CAR-T) cells has revolutionized cancer treatment. However, complexity and high costs involved in manufacturing current greatly inhibit its widespread availability access. To address this, situ therapy, which directly reprograms immune inside body, recently been developed as a promising alternative. Here, an overview of recent progress development synthetic nanomaterials is provided to deliver plasmid DNA or mRNA for reprogramming T macrophages, focusing especially on CAR therapies. Also, main challenges are discussed some approaches overcome these barriers fulfill clinical applications proposed.
Language: Английский
Citations
9
Parasites & Vectors, Journal Year: 2025, Volume and Issue: 18(1)
Published: Feb. 10, 2025
Abstract Background Neospora caninum is an intracellular parasitic protozoon that can infect pregnant animals and cause symptoms such as miscarriage, stillbirth mummified fetuses. It one of the main causes miscarriage in bovines. Apical membrane antigen (AMA) dense granule protein (GRA) are two major antigenic proteins N. caninum. Methods In this study, NcGRA9 recombinant subunit vaccine Ad5-NcAMA1 adenovirus were prepared used to immunize C57BL/6 mice Yanbian yellow cattle. Results IgG, IgG1, IgG2a, IgG2b, IgA IgE antibodies interferon (IFN-γ), interleukin (IL-4) tumor necrosis factor (TNF-α) cytokines significantly higher immunized than control group ( P < 0.0001). The biochemical indexes showed vaccination had no effect on hepatic renal functions. survival rate was 70% with vaccine, 75% 85% combined immunization 10% group. parasite load brain liver tissues groups lower group, detected by fluorescence quantitative PCR cattle, IgA, IgM IFN-γ, IL-4 TNF-α Combined + better either alone. Conclusions kidney functions Our results indicate may be a candidate for bovine neosporosis vaccination. Graphical
Language: Английский
Citations
1
Vaccines, Journal Year: 2025, Volume and Issue: 13(3), P. 304 - 304
Published: March 12, 2025
Respiratory syncytial virus (RSV) remains a significant global health threat, especially to infants, the elderly, and immunocompromised individuals. This review comprehensively explores progress in RSV vaccine development, immune evaluation methods, immunological surrogate. The fusion (F) protein, primary target for has been engineered prefusion conformation elicit potent neutralizing antibodies, while attachment (G) glycoprotein other immunogens are also being explored broaden responses. Advances diverse platforms, ranging from live attenuated protein subunit vaccines cutting-edge mRNA- nanoparticle-based formulations, highlight field’s progress, yet challenges balancing safety, immunogenicity, durability persist. Central these efforts is identification validation of surrogates, which may serve as critical benchmarks efficacy. Neutralizing antibody titers, multifunctional T cell responses, B memory have emerged key correlates protection. However, feasibility surrogates depends on their ability predict clinical outcomes across populations settings. While antibodies block directly, responses essential clearing infected cells preventing severe disease, ensures long-term immunity. Integrating markers into cohesive framework requires standardized assays, robust validation, an in-depth understanding RSV-induced response.
Language: Английский
Citations
1